MA28336A1 - Nouveau derive de benzimidazole a substitution 2-heteroaryle - Google Patents
Nouveau derive de benzimidazole a substitution 2-heteroaryleInfo
- Publication number
- MA28336A1 MA28336A1 MA29214A MA29214A MA28336A1 MA 28336 A1 MA28336 A1 MA 28336A1 MA 29214 A MA29214 A MA 29214A MA 29214 A MA29214 A MA 29214A MA 28336 A1 MA28336 A1 MA 28336A1
- Authority
- MA
- Morocco
- Prior art keywords
- prevention
- benzimidazole derivative
- formula
- atom
- nitrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Il est proposé un activateur de la glucokinase et un remède et/ou moyen de prévention pour le diabète, et un remède et/ou moyen de prévention pour les complications chroniques du diabète telles que rétinopathie, néphropathie, névrose, cardiopathie ischémique, artérioslérose, et un remède et/ou un moyen de prévention pour l'obésité. Un activateur de la glucokinase caractérisé en ce qu'il contient un dérivé 2-hétéroaryle-benzimidazole substitué ayant la formule générale (I-0) ou son sel phartnaceutiquement acceptable : dans cette formule, X représente un atonie de carbone ou un atome d'azote ; X1, X2, X3 et X4 représentent chacun indépendamment un atome de carbone ou un atome d'azote ; l'anneau A représente un anneau hétéro-aromatique à 5 ou 6 éléments porteur d'azote de formule (II) : R1 représente un aryle, etc.; R2 représente un hydroxy etc.; R3 représente un -C1-6 alkyle, etc.; R4 représente un ¿C1-6 alkyle, etc.; X5 représente -O-, etc.; a représente un nombre entier égal à 1, 2 ou 3; q représente un nombre entier allant de 0 à 2; m indique un nombre entier allant de 0 à 2,
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003436992 | 2003-12-29 | ||
JP2004235696 | 2004-08-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA28336A1 true MA28336A1 (fr) | 2006-12-01 |
Family
ID=34742165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA29214A MA28336A1 (fr) | 2003-12-29 | 2006-07-27 | Nouveau derive de benzimidazole a substitution 2-heteroaryle |
Country Status (15)
Country | Link |
---|---|
US (1) | US7728025B2 (fr) |
EP (1) | EP1702919B1 (fr) |
JP (1) | JP4707560B2 (fr) |
KR (1) | KR20060105872A (fr) |
AU (1) | AU2004309287B2 (fr) |
BR (1) | BRPI0418212A (fr) |
CA (1) | CA2553160C (fr) |
EC (1) | ECSP066682A (fr) |
IL (1) | IL176451A0 (fr) |
IS (1) | IS8509A (fr) |
MA (1) | MA28336A1 (fr) |
NO (1) | NO20063475L (fr) |
NZ (1) | NZ548128A (fr) |
RU (1) | RU2329261C2 (fr) |
WO (1) | WO2005063738A1 (fr) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
GB0226930D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
TW200600086A (en) | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
JP2008516935A (ja) | 2004-10-16 | 2008-05-22 | アストラゼネカ アクチボラグ | フェノキシベンズアミド化合物の製造方法 |
RU2398773C2 (ru) | 2004-11-02 | 2010-09-10 | Баниу Фармасьютикал Ко., Лтд. | Арилоксизамещенное производное бензимидазола |
TW200714597A (en) | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
BRPI0622262A2 (pt) | 2005-07-09 | 2011-08-09 | Astrazeneca Ab | composto, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto |
CA2614544C (fr) * | 2005-07-13 | 2013-09-10 | Banyu Pharmaceutical Co., Ltd. | Derive du benzimidazole a substitution par un heterocycle |
JP2007063225A (ja) * | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
WO2007031739A1 (fr) * | 2005-09-16 | 2007-03-22 | Astrazeneca Ab | Composés hétérobicycliques utilisés comme activateurs de la glucokinase |
JP2009509988A (ja) | 2005-09-29 | 2009-03-12 | サノフィ−アベンティス | フェニル−及びピリジニル−1,2,4−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用 |
US7625890B2 (en) | 2005-11-10 | 2009-12-01 | Smithkline Beecham Corp. | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors |
WO2007061923A2 (fr) * | 2005-11-18 | 2007-05-31 | Takeda San Diego, Inc. | Activateurs de la glucokinase |
TW200738621A (en) | 2005-11-28 | 2007-10-16 | Astrazeneca Ab | Chemical process |
EP1963259B1 (fr) * | 2005-12-15 | 2012-02-15 | AstraZeneca AB | Diphenyl-ethers, -amines, -sulfides et -methanes substitues pour le traitement de maladies respiratoires |
HUE028504T2 (en) * | 2006-01-23 | 2016-12-28 | Amgen Inc | Aurora kinase modulators and method for their application |
US7560551B2 (en) | 2006-01-23 | 2009-07-14 | Amgen Inc. | Aurora kinase modulators and method of use |
TW200813039A (en) | 2006-04-19 | 2008-03-16 | Novartis Ag | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
EP2298772A1 (fr) | 2006-10-18 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Composés hétérocycliques condenseé |
TW200825063A (en) | 2006-10-23 | 2008-06-16 | Astrazeneca Ab | Chemical compounds |
TW200825060A (en) | 2006-10-26 | 2008-06-16 | Astrazeneca Ab | Chemical compounds |
TW200833339A (en) | 2006-12-21 | 2008-08-16 | Astrazeneca Ab | Novel crystalline compound |
WO2008136428A1 (fr) * | 2007-04-27 | 2008-11-13 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique à cinq chaînons à teneur en azote |
US8232284B2 (en) | 2007-11-12 | 2012-07-31 | Msd K. K. | Heteroaryloxy quinazoline derivative |
JP4503101B2 (ja) * | 2008-02-06 | 2010-07-14 | 第一三共株式会社 | 新規フェニルピロール誘導体 |
CN102076680B (zh) | 2008-04-28 | 2016-03-02 | 詹森药业有限公司 | 作为脯氨酰羟化酶抑制剂的苯并咪唑 |
PE20110568A1 (es) | 2008-08-04 | 2011-09-07 | Astrazeneca Ab | Agentes terapeuticos 414 |
AU2009280579A1 (en) | 2008-08-15 | 2010-02-18 | Banyu Pharmaceutical Co.,Ltd. | Acetyl pyrrolidinyl indole derivative |
EP2328892B1 (fr) * | 2008-08-29 | 2013-01-16 | Msd K.K. | Dérivé d'oxotétrahydrofurann-2-yl-benzimidazole |
JP5731978B2 (ja) * | 2008-09-26 | 2015-06-10 | インテリカイン, エルエルシー | 複素環キナーゼ阻害剤 |
GB0902406D0 (en) | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Crystalline polymorphic form |
GB0902434D0 (en) | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Chemical process |
WO2010116176A1 (fr) * | 2009-04-09 | 2010-10-14 | Astrazeneca Ab | Dérivé de pyrazolo [4, 5-e] pyrimidine et son utilisation pour traiter le diabète et l'obésité |
AR076220A1 (es) | 2009-04-09 | 2011-05-26 | Astrazeneca Ab | Derivados de pirazol [4,5 - e] pirimidina |
UY32799A (es) | 2009-07-24 | 2011-02-28 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos |
CA2780128A1 (fr) | 2009-11-06 | 2011-05-12 | P. Jeffrey Conn | Aryl- et heteroaryl-sulfones a titre de potentiateurs allosteriques du mglur4, compositions, et methodes pour traiter un dysfonctionnement neurologique |
NZ600367A (en) * | 2009-12-04 | 2013-08-30 | Taisho Pharmaceutical Co Ltd | 2-pyridone compounds |
JP2013514982A (ja) | 2009-12-18 | 2013-05-02 | イデニク プハルマセウティカルス,インコーポレイテッド | 5,5−縮合アリーレン又はヘテロアリーレンc型肝炎ウイルス阻害剤 |
PL2519515T3 (pl) | 2009-12-31 | 2014-04-30 | Novartis Ag | Pochodne pirazyny i ich zastosowanie w leczeniu zaburzeń neurologicznych |
PL2483255T3 (pl) | 2010-07-13 | 2014-03-31 | Novartis Ag | Pochodne oksazyny i ich zastosowanie w leczeniu zaburzeń neurologicznych |
CA2824097A1 (fr) | 2011-01-12 | 2012-07-19 | Novartis Ag | Derives d'oxazine et leur utilisation dans le traitement de troubles neurologiques |
JP6122862B2 (ja) | 2011-10-25 | 2017-04-26 | ヤンセン ファーマシューティカ エヌ.ベー. | 1−(5,6−ジクロロ−1h−ベンゾ[d]イミダゾール−2−イル)−1h−ピラゾール−4−カルボン酸のメグルミン塩製剤 |
CA2919397C (fr) * | 2013-09-09 | 2021-05-18 | Peloton Therapeutics, Inc. | Ethers aryliques comme inhibiteurs h1f-2-alpha pour le traitement du cancer |
WO2016144825A1 (fr) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Composés aromatiques, leurs et utilisations |
US10278942B2 (en) | 2015-03-11 | 2019-05-07 | Peloton Therapeutics, Inc. | Compositions for use in treating pulmonary arterial hypertension |
US10155726B2 (en) | 2015-03-11 | 2018-12-18 | Peloton Therapeutics, Inc. | Substituted pyridines and uses thereof |
WO2016145045A1 (fr) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Compositions s'utilisant dans le traitement du glioblastome |
US10335388B2 (en) | 2015-04-17 | 2019-07-02 | Peloton Therapeutics, Inc. | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
WO2017076900A1 (fr) | 2015-11-02 | 2017-05-11 | Janssen Pharmaceutica Nv | Composé [1,2,4]triazolo[1,5-a]pyridmidine-7-yl |
CA3041412A1 (fr) | 2016-11-02 | 2018-05-11 | Janssen Pharmaceutica Nv | Derives de [1,2,4] triazolo [1,5-a] pyrimidine en tant qu'inhibiteurs de pde2 |
CN109937202B (zh) | 2016-11-02 | 2022-12-30 | 詹森药业有限公司 | 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶化合物 |
AU2017353313C1 (en) | 2016-11-02 | 2022-06-09 | Janssen Pharmaceutica Nv | (1,2,4)triazolo(1,5-a)pyrimidine compounds as PDE2 inhibitors |
AU2022306297A1 (en) | 2021-07-09 | 2024-02-08 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL134354C (fr) | 1963-05-23 | |||
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
EP0726260A1 (fr) | 1995-02-08 | 1996-08-14 | American Cyanamid Company | (1,2,4)Thiadiazoles herbicides |
PE92198A1 (es) | 1996-08-01 | 1999-01-09 | Banyu Pharma Co Ltd | Derivados de 1,4-piperidina disustituida que contienen fluor |
NZ505902A (en) | 1998-01-23 | 2003-08-29 | Upjohn Co | Oxazolidinone compounds useful as antimicrobial agents and combinatorial libraries |
JP2000026430A (ja) * | 1998-07-02 | 2000-01-25 | Taisho Pharmaceut Co Ltd | 2、5、6−置換ベンズイミダゾール化合物誘導体 |
WO2003004488A1 (fr) * | 2001-07-03 | 2003-01-16 | Chiron Corporation | Composes d'indazole benzimidazole utilises comme inhibiteurs de tyrosine et de serine/threonine kinase |
DE10238002A1 (de) | 2002-08-20 | 2004-03-04 | Merck Patent Gmbh | Benzimidazolderivate |
AU2004220234C1 (en) | 2003-02-13 | 2013-01-17 | Msd K.K. | Novel 2-pyridinecarboxamide derivatives |
WO2004076420A1 (fr) | 2003-02-26 | 2004-09-10 | Banyu Pharmaceutical Co., Ltd. | Derives d'heteroarylcarbamoylbenzene |
RU2398773C2 (ru) | 2004-11-02 | 2010-09-10 | Баниу Фармасьютикал Ко., Лтд. | Арилоксизамещенное производное бензимидазола |
TW200745031A (en) | 2005-10-13 | 2007-12-16 | Merck & Co Inc | Acyl indoles, compositions containing such compounds and methods of use |
TW200821284A (en) | 2006-10-03 | 2008-05-16 | Merck & Co Inc | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
-
2004
- 2004-12-28 US US10/582,564 patent/US7728025B2/en active Active
- 2004-12-28 WO PCT/JP2004/019843 patent/WO2005063738A1/fr active Application Filing
- 2004-12-28 CA CA2553160A patent/CA2553160C/fr not_active Expired - Fee Related
- 2004-12-28 KR KR1020067013089A patent/KR20060105872A/ko not_active Application Discontinuation
- 2004-12-28 BR BRPI0418212-0A patent/BRPI0418212A/pt not_active IP Right Cessation
- 2004-12-28 NZ NZ548128A patent/NZ548128A/en unknown
- 2004-12-28 JP JP2005516745A patent/JP4707560B2/ja not_active Expired - Fee Related
- 2004-12-28 AU AU2004309287A patent/AU2004309287B2/en not_active Ceased
- 2004-12-28 RU RU2006127420/04A patent/RU2329261C2/ru not_active IP Right Cessation
- 2004-12-28 EP EP04808192A patent/EP1702919B1/fr active Active
-
2006
- 2006-06-15 IS IS8509A patent/IS8509A/xx unknown
- 2006-06-20 IL IL176451A patent/IL176451A0/en unknown
- 2006-06-28 EC EC2006006682A patent/ECSP066682A/es unknown
- 2006-07-27 MA MA29214A patent/MA28336A1/fr unknown
- 2006-07-28 NO NO20063475A patent/NO20063475L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2329261C2 (ru) | 2008-07-20 |
KR20060105872A (ko) | 2006-10-11 |
NZ548128A (en) | 2010-05-28 |
AU2004309287B2 (en) | 2008-07-31 |
CA2553160C (fr) | 2010-09-28 |
EP1702919B1 (fr) | 2012-05-30 |
WO2005063738A1 (fr) | 2005-07-14 |
EP1702919A1 (fr) | 2006-09-20 |
JP4707560B2 (ja) | 2011-06-22 |
AU2004309287A1 (en) | 2005-07-14 |
JPWO2005063738A1 (ja) | 2007-07-19 |
NO20063475L (no) | 2006-09-28 |
IL176451A0 (en) | 2006-10-05 |
RU2006127420A (ru) | 2008-02-10 |
IS8509A (is) | 2006-06-15 |
CA2553160A1 (fr) | 2005-07-14 |
EP1702919A4 (fr) | 2008-11-12 |
ECSP066682A (es) | 2006-10-25 |
US7728025B2 (en) | 2010-06-01 |
BRPI0418212A (pt) | 2007-04-27 |
US20080070928A1 (en) | 2008-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA28336A1 (fr) | Nouveau derive de benzimidazole a substitution 2-heteroaryle | |
MXPA04005350A (es) | Compuesto de dibencilamina, y uso medicinal del mismo. | |
RU2375363C2 (ru) | Пирролотриазиновые производные анилина, полезные в качестве ингибиторов киназы | |
CA2479133A1 (fr) | Derives de 2,4-diaminopyrimidine | |
DE10178132T1 (de) | Antivirales Mittel | |
EA200600990A1 (ru) | Производные бензосульфониламинопиридин-2-ила и родственные соединения в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы 1 типа (11-бета-hsd-1) для лечения диабета и ожирения | |
CA2646962A1 (fr) | Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete | |
BRPI0510365A (pt) | composto, método de produção de um composto, antagonista do receptor nk2, pró-droga, agente farmacêutico, métodos para antagonizar um recpetor nk2 e para evitar ou tratar doenças gastrintestinais funcionais, e, uso do composto ou uma pró-droga do mesmo | |
EA200500006A1 (ru) | Лекарственное средство для лечения нейродегенеративных заболеваний | |
CA2497868A1 (fr) | Composes heterocycliques | |
MX2009010790A (es) | Derivados de heteroarilo biciclico fusionados. | |
EA200701035A1 (ru) | Замещенные n-сульфониламинобензил-2-феноксиацетамидные соединения | |
CA2412941A1 (fr) | Composes de piperidine s'utilisant en tant qu'inhibiteurs ccr-3 | |
FI951417A (fi) | Bifenyylijohdannaiset | |
MA30355B1 (fr) | Derives d'azabicyclo [3. 1. 0] hexyle utilises comme modulateurs des recepteurs de la dopamine d3 | |
RU2008119651A (ru) | Производные дикарбоновых кислот и их применение | |
RU2008119465A (ru) | Производные циклопропилуксусной кислоты и их применение | |
WO2003024441A1 (fr) | Nouvelle utilisation de composes tricycliques | |
MY169179A (en) | Novel piperidine compound or salt thereof | |
JP2006523698A5 (fr) | ||
MA33352B1 (fr) | Derives de cyclopenta[c]pyrrolylalkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique | |
RU92016545A (ru) | Гетероциклические соединения, способ их получения и фармацевтическая композиция | |
MA38885A1 (fr) | Dérivés d'éthynyle modulateurs allosteriques positifs (pam) du recepteur metabotropique du glutamate 4 (mglu4) | |
JP2018529643A (ja) | ユビキチン化−プロテアソーム系に関連する化合物および薬学的組成物 | |
MX2009002905A (es) | Derivados de 3-amino-piridina para el tratamiento de trastornos metabolicos. |